- to determine whether Avelumab improves overall survival (OS) compared to observation in patients with high-risk primary triple negative breast cancer who have completed treatment with curative intent including surgery of the primary tumor, neo- or adjuvant chemotherapy, and (if indicated) radiotherapy.